drugset / Trial / NCT06224257
Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Phase 2
Recruiting
41 enrolled
Institute of Hematology & Blood Diseases Hospital, China
YL-Pharma · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of Linperlisib, the PI3K delta inhibitor for patients with relapsed/refractory large granular T lymphocytic leukemia.
Timeline
- Start
- 2023-12-03
- Primary completion
- 2025-10-31
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linperlisib | Small molecule | 80 mg | Oral |